NCT05256225 2026-04-16
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
19 trialsNCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06952504 2026-04-13
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07044336 2026-04-13
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Phase 3 Recruiting
NCT07198074 2026-04-13
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06989112 2026-04-08
DE-01
AstraZeneca
Phase 3 Recruiting
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06340568 2026-03-31
Fern-EC-01
BioNTech SE
Phase 3 Recruiting
NCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05691010 2026-02-04
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06463028 2025-12-24
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Faeth Therapeutics
Phase 2 Recruiting
NCT07108270 2025-12-22
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
Phase 2 Recruiting
NCT06795009 2025-12-11
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT06758557 2025-01-23
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Huabo Biopharm Co., Ltd.
Phase 1/2 Recruiting
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT06522828 2024-10-21
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Recruiting